NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

August 18, 2026

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

The EU-Japan Biotech Business Mission focuses on business development and partnering between European and Japanese life science companies. The programme begins in September with digital business training, market intelligence and online partnering. The focus will be on activities in Japan 5–9 October, including the EU-Japan Biotech & Pharma Partnering Conference in Osaka and participation in BioJapan in Yokohama.

The selection follows NextCell’s participation in the first round of the Japan Entry Acceleration Program (JEAP), initiated and funded by the Japan External Trade Organization (JETRO). NextCell was one of only ten companies globally, and the only Swedish company, selected for the programme’s first cohort. Following the completion of JEAP, NextCell was encouraged by JETRO to apply for the EU-Japan Biotech Business Mission.

NextCell’s activities in Japan have provided the Company with access to industry and regulatory stakeholders and a deeper understanding of potential development pathways for NXTCL-T1D. Discussions with, among others, the PMDA, regulatory advisors and industry stakeholders have also provided greater clarity on potential models for future development and commercialisation, including the possibility of retaining manufacturing outside Japan.

In Hong Kong, NextCell has previously established the wholly owned subsidiary NextCell Hong Kong Limited as part of the Company’s strategy for Asia. NextCell is also a member of the Swedish Chamber of Commerce in Hong Kong and the Hong Kong Chamber of Commerce in Sweden. The office and membership in HSITP now represent a further step in strengthening the Company’s local presence.

“Over the past year, we have implemented our Asia strategy step by step. Our activities in Japan and Hong Kong have provided us with concrete regulatory and industry contacts, strengthened our network and clarified potential pathways for further development and commercialisation. The next step is to translate these efforts into partnerships for NXTCL in Asia,” says Mathias Svahn, CEO of NextCell.

For more information, please contact:
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com

Website:: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company’s lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hongkong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.

Download attachmentRead full press release on Cision (external link)
2020-04-29
NextCell Pharma AB publishes its interim report for September 2019 - February 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income amounted to SEK 1 364 645 (435 051). · Operating result amounted to SEK -4 228 449 (-3 552 444). · Earnings per share* amounted to SEK -0,22 (-0,31). · Cash and bank amounted to SEK 10 700 725 (6 886 879). · Solidity** amounted to 80,2 (85,0) %. First six month (2019-09-01
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income...
Read moreRead more
2020-03-20
NextCell in discussions about patients with covid-19
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell. "We advise against speculative share purchases in the
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this informa...
Read moreRead more
2020-03-11
The stem cell company NextCell Pharma is preparing for a pivotal phase III trial
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (...
Read moreRead more
2020-02-21
The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to...
Read moreRead more
2020-02-10
Participates in innovation projects for cell-based products
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced M...
Read moreRead more
2020-02-04
NextCell to present its progress at Swiss Nordic Bio 2020
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich. Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company w...
Read moreRead more
2020-01-31
Interim Report 1 2019/2020
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31.  First quarter (2019-09-01 until 2019-11-30) · Operating income amounted to SEK 1 222 087 (73 745). · Operating result amounted to SEK -3 755 926 (-5 440 809).      · Earnings per share* amounted to SEK -0,20 (-0,38). · Cash and bank
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Com...
Read moreRead more
2019-12-11
Extended permission from the Medical Products Agency
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale dist...
Read moreRead more